MA08.016h, Treatment of Pulmonary Artery Hypertension with Intravenous, Subcutaneous, and Inhaled Pharmacologic Agents

By April 21, 2025: Billing and clinical teams must review the full MA08.016h policy text to identify specific medical necessity criteria for PAH pharmacologic treatments. Update prior authorization templates and clinical documentation requirements in the EMR to align with new criteria. Providers should document medical necessity according to updated guidelines for all intravenous, subcutaneous, and inhaled PAH medications. Ensure billing team is aware of any new documentation requirements to avoid claim denials. Access full policy at https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=04&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#medicare-advantage-ma08-016h-treatment-of-pulmonary-artery-h